Trial Profile
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms NZ-DTX-001
- Sponsors LIDDS
- 29 Dec 2021 According to a LIDDS media release, the company plans to submit detailed study data for publication in a relevant journal.
- 29 Dec 2021 Results published in LIDDS Media Release
- 22 Dec 2021 Status changed from active, no longer recruiting to discontinued.